Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer
Journal of Clinical Oncology · 20.11.2026 · 44 (33) · 3284-3284
DOI: 10.1200/jco-26-01219 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2026. Verfasst von Hirotaka Suto. Beteiligte Einrichtung: Hirotaka Suto, MD, PhD, Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Hirotaka Suto, MD, PhD, Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan.
ORCID-Profile: Hirotaka Suto
Zitieren
APA
Suto, H. (2026). Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer. Journal of Clinical Oncology, 44(33), 3284-3284. https://doi.org/10.1200/jco-26-01219
Vancouver
Suto H. Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer. Journal of Clinical Oncology. 2026;44(33):3284-3284. doi:10.1200/jco-26-01219
BibTeX
@article{Suto2026,
author = {Suto, Hirotaka},
title = {Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {33},
pages = {3284--3284},
doi = {10.1200/jco-26-01219}
}
EUVIMED